Ribozyme Effector Gene in Dengue Fever Transmission and Disease Control
AssigneeUniversity of Notre Dame
InventorMalcolm J. Fraser
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Notre Dame
InventorMalcolm J. Fraser
Estimating the term…
Disclosed are anto-DENV ribozyme based methods and compositions useful in the inhibition and control of all Dengue fever serotypes (designated DENV 1 through 4). A group of anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) are presented that target DENV-2 NGC genomes in situ. Methods for specifically targeting a highly conserved 5′-3′ cyclization sequence (CS) region that is common to all serotypes of the DENV are provided. The anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) specifically target two different uracil bases on the positive sense genomic strand. The invention provides an RNA based approach for transgeneic suppression of DENV in transformed mosquitoes using a group of specifically designed introns that trans-splice a new RNA sequence downstream of a targeted site. The aDENV-GrpIs target DENV infected genomes and thus provide a method for inhibiting the spread of Dengue fever. An αDENV-GrpI 9v1 is presented that is designed to be active against all forms of Dengue virus, and to effectively target the DENV-2 NGC genome in a sequence specific manner
A method for inhibiting mosquito transmission of Dengue virus infection to an animal, said method comprising:
An αDENV-GrpI intron genetic construct for use in the transformation of a mosquito comprising:
Dependencies are inferred from the claim text.